文献速递淋巴瘤

肿瘤微环境中检查点蛋白表达决定经典霍奇金淋巴瘤患者的结局

Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients.
PubMed 文献 · Blood Adv · 2022-01-01

该研究通过基因表达谱分析(n=88)、CIBERSORT及多重免疫组化(n=131)刻画经典霍奇金淋巴瘤肿瘤微环境免疫特征并与生存关联。高比例检查点蛋白阳性免疫细胞群与不良总生存相关(5年OS 76% vs 96%;P=.010),多变量分析中为独立预后因素(HR 4.34;95%CI 1.05-17.91;P=.043)。该检查点分子基因特征在290例诊断样本验证队列(P<.001)及84例复发样本扩展队列(P=.048)中均与较差生存相关。

要点

  • 高比例检查点蛋白阳性免疫细胞群与不良总生存相关(5年OS 76% vs 96%;P=.010)。
  • 多变量分析中该免疫细胞群为总生存的独立预后因素(HR 4.34;95%CI 1.05-17.91;P=.043)。
  • 检查点分子基因特征在验证队列(P<.001)和复发扩展队列(P=.048)中均与较差生存相关。

核心结论

  • 研究证明T细胞和巨噬细胞介导的检查点系统对经典霍奇金淋巴瘤患者生存有影响。

研究设计与样本

  • 采用基因表达谱分析(n=88)、CIBERSORT和多重免疫组化(n=131)刻画经典霍奇金淋巴瘤肿瘤微环境免疫特征并与生存关联。
  • 验证队列为290例诊断经典霍奇金淋巴瘤样本,扩展队列为84例经典霍奇金淋巴瘤复发样本。

主要发现

  • 基因表达分析将肿瘤分为T细胞炎症型和非T细胞炎症型肿瘤微环境亚组。
  • 非T细胞炎症型肿瘤微环境中多个巨噬细胞相关基因上调,基于免疫细胞比例样本按T细胞和巨噬细胞含量聚类。
  • 高比例检查点蛋白(程序性死亡蛋白1、PD-1配体、吲哚胺2,3双加氧酶1、淋巴细胞活化基因3及T细胞免疫球蛋白和黏蛋白结构域蛋白3)阳性免疫细胞的聚类与不良总生存相关(5年OS 76% vs 96%;P=.010),多变量分析中为总生存的独立预后因素(HR 4.34;95%CI 1.05-17.91;P=.043)。
  • 高比例检查点蛋白的经典霍奇金淋巴瘤样本过表达编码溶细胞因子的基因,提示其免疫学活跃。
  • 该检查点分子基因特征在290例诊断经典霍奇金淋巴瘤样本验证队列中与较差生存相关(P<.001),在84例经典霍奇金淋巴瘤复发样本扩展队列中亦与较差生存相关(P=.048)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Emerging evidence indicates a major impact for the tumor microenvironment (TME) and immune escape in the pathogenesis and clinical course of classical Hodgkin lymphoma (cHL). We used gene expression profiling (n = 88), CIBERSORT, and multiplex immunohistochemistry (n = 131) to characterize the immunoprofile of cHL TME and correlated the findings with survival. Gene expression analysis divided tumors into subgroups with T cell-inflamed and -noninflamed TME. Several macrophage-related genes were upregulated in samples with the non-T cell-inflamed TME, and based on the immune cell proportions, the samples clustered according to the content of T cells and macrophages. A cluster with high proportions of checkpoint protein (programmed cell death protein 1, PD-1 ligands, indoleamine 2,3 dioxygenase 1, lymphocyte-activation gene 3, and T-cell immunoglobulin and mucin domain containing protein 3) positive immune cells translated to unfavorable overall survival (OS) (5-year OS 76% vs 96%; P = .010) and remained an independent prognostic factor for OS in multivariable analysis (HR, 4.34; 95% CI, 1.05-17.91; P = .043). cHL samples with high proportions of checkpoint proteins overexpressed genes coding for cytolytic factors, proposing paradoxically that they were immunologically active. This checkpoint molecule gene signature translated to inferior survival in a validation cohort of 290 diagnostic cHL samples (P < .001) and in an expansion cohort of 84 cHL relapse samples (P = .048). Our findings demonstrate the impact of T cell- and macrophage-mediated checkpoint system on the survival of patients with cHL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Karihtala K, Leivonen SK, Karjalainen-Lindsberg ML, et al. Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood Adv. 2022. PMID: 34941990. doi:10.1182/bloodadvances.2021006189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。